ABSI — Absci Corporation

ABSI Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $400,000 for Q3 2025, attributed to partnered programs.
• R&D Expenses: Increased to $19.2 million from $18 million year-over-year, driven by internal program advancements.
• SG&A Expenses: Decreased to $8.4 million from $9.3 million, primarily due to lower personnel-related costs.
• Cash Position: $152.5 million as of September 30, 2025, up from $117.5 million as of June 30, 2025. The company believes this will fund operations into 2028.

2. Strategic Updates and Business Highlights

• ABS-101: Interim phase one results show an extended half-life compared to first-generation competitors, but not against next-generation programs. The company plans to seek a partner for ABS-101 and will not pursue further internal development beyond phase one.
• ABS-201: Development for androgenetic alopecia (AGA) is ahead of schedule, with a phase 1/2a trial set to start in December 2025. The company is also expanding ABS-201's development into endometriosis, with a phase two trial expected to begin in 2026.
• KOL Engagement: New advisory board members include leading dermatologists, enhancing the program's credibility and outreach.
• AI Platform: Continued expansion of AI capabilities is generating interest for potential partnerships.

3. Forward Guidance and Outlook

• Clinical Trials: Expect interim proof of concept readouts for ABS-201 in AGA in late 2026 and for endometriosis in 2027.
• Partnerships: Anticipate signing one or more drug creation partnerships with large pharmaceutical companies by year-end 2025.
• Market Opportunities: Both AGA and endometriosis represent multibillion-dollar market potentials with significant unmet medical needs.

4. Bad News, Challenges, or Points of Concern

• ABS-101 Development: The decision to halt further internal development for ABS-101 raises concerns about the asset's potential and market position.
• Competitive Landscape: The company faces competition in both AGA and endometriosis, particularly with emerging therapies like HMI-115, which has shown proof of concept in endometriosis.
• Trial Design Risks: Concerns were raised about recruitment and design for the endometriosis trial, especially based on learnings from competitor trials.

5. Notable Q&A Insights

• Partnerships for ABS-101: The company has not yet shared data with potential partners but plans to do so soon. They are exploring first-in-class indications for ABS-101 to expand the buyer universe.
• Endometriosis Trial Design: The company aims for a well-structured trial design to avoid enrollment issues seen in competitor trials. They are focused on patients with significant pain and those currently on GnRH therapies.
• Efficacy Expectations: Interim data for AGA is expected in the second half of 2026, with a focus on significant hair regrowth metrics.
• Prolactin Mechanism: There is confidence that ABS-201 will work across all endometriosis patients due to the overexpression of prolactin receptors in lesions, indicating a broad potential patient base.

Overall, Absci Corporation is strategically focusing on its promising ABS-201 program while navigating challenges in its pipeline and competitive landscape.